Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
AP Photo/Mark Lennihan
The Senate has passed Sen. Ron Johnson's "right to try" bill, which would expand terminally ill patients' access to treatments that haven't yet been approved by the FDA. The bill passed by unanimous consent, and should help clear the way to vote on a larger FDA bill before senators break for the August recess.
Why it matters: On its face, right-to-try sounds simple enough: Why not let patients who are already dying, who have already tried everything else, take a shot at an unproven therapy? But the risk with unproven drugs isn't only that they might be ineffective — they also can carry side effects that might make patients' suffering worse. Regulators have also worried about maintaining the integrity of controlled clinical trials.
To address some of those concerns, the Senate bill says the FDA can't use data from right-to-try patients in its product reviews. The bill also wouldn't force drug makers to make their unproven products available — it simply says the federal government can't stand in the way of that transaction.